Qingdao Baheal Medical INC. Total Liabilities
Qingdao Baheal Medical INC. total liabilities. Based on the latest financial reports, Qingdao Baheal Medical INC. (301015) has total liabilities worth CN¥5.67 Billion CNY (≈ $829.59 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Qingdao Baheal Medical INC. defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Qingdao Baheal Medical INC. (2018–2025)
Total liabilities of Qingdao Baheal Medical INC. from 2018 to 2025. This chart illustrates how Qingdao Baheal Medical INC.'s total liabilities have evolved over time, based on quarterly financial data. Check 301015 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Qingdao Baheal Medical INC. Competitors by Total Liabilities
The table below lists competitors of Qingdao Baheal Medical INC. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Southchip Semiconductor Technology (Shanghai) Co. Ltd. A
SHG:688484
|
China | CN¥751.22 Million |
|
SolarEdge Technologies Inc
NASDAQ:SEDG
|
USA | $1.85 Billion |
|
Shanghai V-Test Semiconductor Tech Co. Ltd. A
SHG:688372
|
China | CN¥4.57 Billion |
|
La Comer S.A.B. de C.V
MX:LACOMERUBC
|
Mexico | MX$8.02 Billion |
|
Suzhou TZTEK Technology Co Ltd
SHG:688003
|
China | CN¥1.98 Billion |
|
Kalbe Farma Tbk PT
JK:KLBF
|
Indonesia | Rp7.31 Trillion |
|
Weis Markets Inc
NYSE:WMK
|
USA | $656.28 Million |
|
Sigdo Koppers
SN:SK
|
Chile | CL$2.96 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Qingdao Baheal Medical INC.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 301015 total assets.
Liquidity & Leverage Metrics
Qingdao Baheal Medical INC. Total Liabilities Ratios Explained
Qingdao Baheal Medical INC. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.43 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.66 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Qingdao Baheal Medical INC.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Qingdao Baheal Medical INC. (2018–2025)
The table below shows the annual total liabilities of Qingdao Baheal Medical INC. from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥5.37 Billion ≈ $785.86 Million |
+19.13% |
| 2024-12-31 | CN¥4.51 Billion ≈ $659.65 Million |
+36.69% |
| 2023-12-31 | CN¥3.30 Billion ≈ $482.61 Million |
+16.30% |
| 2022-12-31 | CN¥2.84 Billion ≈ $414.97 Million |
+16.76% |
| 2021-12-31 | CN¥2.43 Billion ≈ $355.41 Million |
-4.83% |
| 2020-12-31 | CN¥2.55 Billion ≈ $373.44 Million |
+20.12% |
| 2019-12-31 | CN¥2.12 Billion ≈ $310.90 Million |
+37.78% |
| 2018-12-31 | CN¥1.54 Billion ≈ $225.65 Million |
-- |
About Qingdao Baheal Medical INC.
Qingdao Baheal Medical INC. engages in the research and development, production, wholesale, and retail of pharmaceutical products in China, the United States, Hong Kong, and the United Kingdom. The company offers bone health drugs under the D-Cal brand name; digestive drugs under the Mite brand name; liver disease drugs under the Fuzhenghuayu brand name; and urological drugs under the Betanli, Ha… Read more